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After the first reports about a protective effect on coronary heart disease (CHD) published
more than 40 years ago, wide interest in the therapeutic use of n−3 polyunsaturated fatty
acids (n−3 PUFA) aroused. Since then, many studies and meta-analyses have reported a
significantly reduced risk of CHD and CV death due to fish and n−3 PUFA intake. Some
of the overviews reported a significant reduction of risk of sudden cardiac death, all-cause
death, and nonfatal CV events. On the other side, recent clinical trials had mixed findings,
raising concern about the consistency of the evidence on n−3 PUFA.We critically reviewed
recent large clinical trials reporting data on the antiarrhythmic effects of n−3 PUFA in dif-
ferent clinical settings, i.e., patients with CHD, heart failure, with implantable cardioverter
defibrillator, and at risk of atrial fibrillation, in order to summarize the results which are
available up to date and possibly give “substantiated” fuel to the debate on the conflicting
results of n 3 PUFA.−
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INTRODUCTION
After the first report about a protective effect on coronary heart
disease (CHD) published more than 40 years ago, wide interest
in the therapeutic use of n−3 polyunsaturated fatty acids (n−3
PUFA) aroused (Bang et al., 1971; Bang and Dyerberg, 1972).
Since then, many studies have been performed, increasing our
knowledge on the cardiovascular (CV) effects of n−3 PUFA. Var-
ious meta-analyses have reported a significantly reduced risk of
CV events, primarily due to reduction of CHD and CV death due
to fish and n−3 PUFA intake (He et al., 2004; Leon et al., 2008;
Marik and Varon, 2009; Mente et al., 2009). Some of the overviews
reported a significant reduction of risk of sudden cardiac death
(SCD; Leon et al., 2008; Marik and Varon, 2009), all-cause death
(Marik and Varon, 2009), and non-fatal CV events (Marik and
Varon, 2009). However, several questions remain open to date,
e.g., the mechanisms accounting for the benefit observed in clinical
studies as well as a possible heterogeneity of the effect in different
populations. On the other side, recent clinical trials had mixed
findings, raising concern about the consistency of the evidence on
n−3 PUFA.
Among the many physiological effects which n−3 PUFA are
supposed to have, the antiarrhythmic effect is the most interesting
one but is challenging to be documented in humans because of
the absence of reliable physiological measures or biomarkers to
quantify the antiarrhythmic potential of n−3 PUFA on SCD.
We critically reviewed recent large clinical trials reporting data
on the antiarrhythmic effects of n−3 PUFA in different clinical
settings, i.e., patients with CHD (Marchioli et al., 2002; Yokoyama
et al., 2007; Rauch et al., 2010), heart failure (HF; Tavazzi et al.,
2008), with implantable cardioverter defibrillator (ICD; Leaf et al.,
2005; Raitt et al., 2005; Brouwer et al., 2006), and at risk of atrial
fibrillation (AF; Calo et al., 2005; Kowey et al., 2010; Nodari et al.,
2011), in order to summarize the results which are available up
to date and possibly give “substantiated” fuel to the debate on the
conflicting results of n−3 PUFA.
CORONARY HEART DISEASE
The first intervention study suggesting an antiarrhythmic effect
of n−3 PUFA was the Diet and Reinfarction Trial (DART) study
carried out on 1989 (Burr et al., 1989). In 2033 post-myocardial
infarction (MI) men, those advised to eat fat fish two to three
times a week had a significant 29% reduction in fatal MI com-
pared to those not advised so. This benefit appeared early after the
start of the trial and was hypothesized to be due to a reduction of
sudden death. Some years later, a decreased mortality and sudden
death were observed in post-MI patients receiving a Mediterranean
alpha-linolenic acid (ALA)-rich diet (de Lorgeril et al., 1994). In
another trial, patients with suspected MI and receiving fish oil
(2 g n−3 PUFA daily) or mustard seed oil (containing 2.9 g of
ALA per day) experienced fewer sudden deaths than the placebo
group (Singh et al., 1997). An analysis of the US Physician’s Health
Study, a prospective study on 20,551 male physician followed for
up to 11 years, showed that fish consumption≥ once per week was
associated with a 52% reduction in the risk of SCD as compared
with men with lower fish intake (Albert et al., 1998). Later, a new
report from this study showed an inverse relationship between
blood levels of long chain n−3 PUFA and risk of SCD (Albert
et al., 2002).
The strongest evidence suggesting an antiarrhythmic effect of
n−3 PUFA was provided by GISSI-Prevenzione, an open-label,
randomized, controlled trial performed to test the efficacy of an
oral administration of n−3 PUFA (1 g daily) and vitamin E on
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morbidity and mortality in 11,323 Italian patients with recent
(MI< 3 months; Gruppo Italiano per lo Studio della Soprav-
vivenza nell’Infarto miocardico, 1999). After 3.5 years of follow-
up, n−3 PUFA therapy significantly reduced the first combined,
primary endpoint (death, non-fatal myocardial, and non-fatal
stroke) by 15% (95% confidence interval, CI: 3–27, P = 0.02) as
well as the co-primary endpoint (cardiovascular death plus non-
fatal MI plus non-fatal stroke) by 20% (95% CI: 6–32,P = 0.006) as
compared to the control group. Secondary analyses of the compo-
nents of the primary endpoints showed that almost all the benefit
observed in the combined endpoints was attributable to the reduc-
tion in fatal events: total mortality 20%, (95% CI: 6–23%); CV
death 30% (95% CI: 13–44%); CHD death 35% (95% CI: 16–
49%); and SCD 44% (95% CI: 24–60%). An intention-to-treat
analysis of GISSI-Prevenzione, adjusted for interaction between
treatments, was aimed at assessing the time course of benefit on
fatal events. It showed an early divergence of the survival curves
for n−3 PUFAs and control groups after randomization, with total
mortality being significantly lowered after only 3 months of treat-
ment (RR 0.59, 95% CI: 0.36–0.97; P = 0.037; Marchioli et al.,
2002). Likewise, the reduction in risk of SCD was already sta-
tistically significant at 4 months (RR 0.47; 95% CI: 0.219–0.995;
P = 0.048). A similarly significant, although delayed, pattern was
observed for CV, cardiac, and CHD deaths after 6–8 months of
treatment. In agreement with previous evidence coming from both
experimental and human studies, such findings suggested that the
early benefits of n−3 PUFA may be due to their antiarrhythmic
activity (McLennan et al., 1992, 1993; Kang and Leaf, 1994, 1995,
1996; Kang et al., 1995; Sellmayer et al., 1995; Siscovick et al., 1995;
Xiao et al., 1995, 1997, 1998; Christensen et al., 1997; Billman et al.,
1999).
GISSI-Prevenzione trial had several strengths. It was adequately
sized (the largest prospective controlled trial that investigated the
effect of a dietary-derived drug on CV events) in a population
of patients at high-risk of arrhythmia, with a reliable statistical
power to show that n−3 PUFA could decrease hard endpoints
of morbidity and mortality in a clinically and statistically signif-
icant manner. As to clinical relevance, it is worth noting that for
every 1000 post-MI patients treated for 1 year with 1 g daily of
n−3 PUFA, 5.7 lives were saved. Such protective effect with n−3
PUFA treatment observed in GISSI-Prevenzione is comparable in
the magnitude to the results of other drugs which are now con-
sidered therapeutic cornerstone in cardiovascular prevention. For
instance, in the LIPID trial, 5.2 lives could be saved treating with
pravastatin for 1 year 1000 patients with hypercholesterolemia and
CHD (The Long-Term Intervention with Pravastatin in Ischaemic
Disease (LIPID) Study Group, 1998). Although some changes in
the management of post-MI patients occurring over years have
to be considered, many aspects of GISSI-Prevenzione are reassur-
ing as to the transferability of the results to clinical practice for
post-MI patients,: (a) the trial was very large and performed in
the framework of a “usual care” clinical setting, (b) it was car-
ried out in a country-wide network of hospitals within the Italian
national public health service, and (c) had a pragmatic design
aimed at not interfering with daily clinical practice. It might be
also argued that in populations at high CV risk, such as those
with a western lifestyle, n−3 PUFA might have greater benefit
than in the Italian population, known to be at low risk for CHD
mainly for the Mediterranean dietary habits (Marckmann and
Gronbaek, 1999). The benefit of n−3 PUFA treatment can be
considered as additive to those of recommended pharmacological
treatments and lifestyle interventions. Indeed, patients enrolled in
GISSI-Prevenzione received n−3 PUFA treatment on the top of
preventive pharmacological treatments, including aspirin, beta-
blockers, angiotensin-converting enzyme (ACE) inhibitors and
cholesterol-lowering drugs, as well as of lifestyle interventions
leading at the end of the trial to a positive modification of dietary
habits with increase of the (already relatively high) intake of olive
oil, fruit, vegetables, and fish (Barzi et al., 2003).
Recent randomized clinical trials did not confirm the antiar-
rhythmic effect of n−3 PUFA. The Japan EPA Lipid Intervention
Study (JELIS; Yokoyama et al., 2007) was a large scale trial con-
ducted in 18,000 hypercholesterolemic Japanese patients who were
randomized to n−3 PUFA treatment (1.8 g/day) in combination
with statin vs. statin alone. After a mean follow-up of 4.6 years, the
patients in the n−3 PUFA group experienced a reduction of 19%
of CHD events. The benefit of n−3 PUFA was limited to non-fatal
CHD events, particularly unstable angina, whilst the effect on fatal
events was not significant, particularly on SCD. Such apparent lack
of the antiarrhythmic effect in this population of patients could be
related to some specific aspects of JELIS. Firstly, the assumption of
reaching a statistical power of 80% for detecting a relative reduc-
tion of 25% in the primary endpoint was respected, but the rate of
SCD (i.e., a secondary outcome measure) in the JELIS population
was extremely low. Only 35 of the 18,645 participants (0.19%) in
JELIS experienced a SCD during 5 years of follow-up. As a result
the study lacked sufficient power, to detect an effect on mortality
in general and specifically on SCD (statistical power of 13, 7, and
5% to detect a relative reduction of 30, 20, and 10% of the risk in
SCD, respectively, Table 1). Another relevant aspect of JELIS was
the administration of 1.8 g daily of eicosapentaenoic acid (EPA)
on the top of a high dietary intake of n−3 PUFA. A pooled analysis
of prospective and randomized studies suggested the existence of
a dose-response curve for the antiarrhythmic effect of n−3 PUFA
on SCD, which seems to have a steep slope at modest levels of n−3
PUFA intake (<750 mg) and a plateau thereafter, higher doses of
n−3 PUFA having been hypothesized not having further beneficial
effects on SCD (Mozaffarian and Rimm, 2006). Because of the high
fish intake (e.g., median 900 mg/day) of Japanese people (Iso et al.,
2006), this “threshold” effect might play a role in the JELIS results,
e.g., by magnifying anti-atherosclerotic, anti-inflammatory, and
plaque stabilizing effects of the high daily supplement of n−3
PUFA (1800 mg) while the benefit on arrhythmic events was not
detectable due to the low rate of such events in this population.
Like in the case of JELIS, the lack of clinical benefit reported in
a previous study evaluating the effect of 4 g/day of n−3 PUFA,
compared to corn oil, in 300 post-MI patients (4–8 days; Nilsen
et al., 2001), may be due to both a “threshold effect” as well as to
an insufficient study power due to the low event rate observed in
the study.
In 2010 the results of the OMEGA trial have been published.
The study was a randomized, double-blind, placebo-controlled,
multicentre trial, testing the effect of n−3 PUFA (1000 mg/day
for 12 months) on the rate of SCD in 3851 patients with MI
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in the previous 3–14 days (Rauch et al., 2006, 2010). Secondary
endpoints of OMEGA included total mortality and non-fatal
CV events. Also, OMEGA showed no difference in the incidence
of SCD between n−3 PUFA and placebo groups (1.5 vs. 1.5%;
P = 0.84). No difference with regard to secondary endpoints was
found (total mortality 4.6 vs. 3.7%; P = 0.18; major cerebrovas-
cular and CV events 10.4 vs. 8.8%; P = 0.1; revascularization in
survivors 27.6 vs. 29.1%; P = 0.34). Some methodological aspects
of the OMEGA trial deserve to be considered. It was assumed that
the proportion of SCD during the study should have been 44%
of total deaths, therefore resulting in a SCD rate of 3.5% in the
control group at the end of the study. The observed incidence of
SCD was lower (1.5% in both groups), i.e., less than the half of
the expected one, thus making the trial underpowered to detect
an antiarrhythmic effect of n−3 PUFA (Table 1). Another aspect
to be considered is the treatment of post-MI patients enrolled in
OMEGA Study. Acute revascularization was performed in 81%
of patients. Short- and long-term guideline-driven medication
was administered in the vast majority of patients: b-blockers, ACE
inhibitors/angiotensin receptor blockers (ARB), statins, acetylsal-
icylic acid, and clopidogrel were prescribed to 94, 91, 94, 95, and
88% of patients, respectively. The large use of guideline-based ther-
apy after MI may have contributed to the low rate of fatal events,
so reducing the room for improvement due to n−3 PUFA treat-
ment, and, on the other hand, may also reduce the transferability
of OMEGA results to the treatment of post-MI patients that, to
date, still appear substantially different in clinical practice (Kotseva
et al., 2009a,b).
The results of Alpha Omega Trial have been published a few
weeks after the publication of OMEGA (Kromhout et al., 2010).
Alpha Omega was a multicenter, double-blind, placebo-controlled
trial testing the effects of n-3 PUFA on the rate of cardiovas-
cular events among 4837 patients, 60 through 80 years of age,
who have had a MI. Patients were randomly assigned to use for
40 months one of four types of margarine enriched with marine
n−3 PUFA with a targeted additional daily intake of (a) 400 mg
of a combination of EPA and docosahexaenoic acid (DHA); (b)
plant-derived n−3 PUFA, with a targeted additional daily intake
of 2 g of alpha-linolenic acid (ALA); (c) marine (400 mg/day) plus
plant-derived (2 g/day) n−3 PUFA; (e) placebo. Neither marine-
nor plant-derived n−3 PUFA reduced the primary endpoint, i.e.,
the rate of major CV events, including fatal and non-fatal CV
events and cardiac interventions (hazard ratio, HR with EPA–
DHA, 1.01; 95% CI: 0.87–1.17; P = 0.93; HR with ALA, 0.91; 95%
CI: 0.78–1.05; P = 0.20). n−3 PUFA did not reduce the secondary
endpoints, including ventricular arrhythmia-related events (SCD,
fatal and non-fatal cardiac arrest, and placement of implantable
cardioverter–defibrillators; HR with EPA–DHA, 0.90; 95% CI:
0.65–1.26; P = 0.55; HR with ALA, 0.79; 95% CI: 0.79–1.19;
P = 0.16). Alpha Omega was a factorial trial and therefore only
the two-way analyses comparing patients who received EPA–DHA
to those not receiving marine n−3 PUFA as well as comparing
patients who received ALA to those not receiving plant-derived
n−3 PUFA were published. In the former case, 2404 patients with
a mean daily supplementation of EPA-DHA of 400 mg plus a mean
daily supplementation of ALA of 1008 mg was compared to 2433
patients with a mean daily supplementation of ALA of 984 mg.
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In the latter case, 2409 patients with a mean daily supplementa-
tion of EPA-DHA of 201 mg plus a mean daily supplementation
of ALA of 2000 mg was compared to 2428 patients with a mean
daily supplementation of EPA-DHA of 196 mg. In other words,
the effect of n−3 PUFA was not compared with a pure “placebo.”
The assessment of the effect of n−3 PUFA was likely to be biased
because all the patients were receiving n−3 PUFA and in the case
of marine n−3 PUFA the comparison was between two groups
receiving approximately a total of 1.4 vs. 1.0 g of n−3 PUFA.
The administration of n−3 PUFA in all patients of the Alpha
Omega trial has made the results difficult to interpret and might
have obscured the antiarrhythmic effect of n−3 PUFA if a thresh-
old for the antiarrhythmic effect truly exists (de Lorgeril et al.,
1994; Leaf, 1999; Zatonski et al., 2008). More recently the results
of SU.FOL.OM3 study have been published (Galan et al., 2010).
Among 1863 patients with CHD, neither a treatment with n−3
PUFA (600 mg/day), nor treatment with B vitamins was associ-
ated with a significant effect on the occurrence of hard coronary
events, a composite endpoint including sudden death, after a mean
follow-up of 4.2± 1.0 years. No information on sudden death was
provided in this study.
HEART FAILURE
The GISSI-Prevenzione results showed that systolic dysfunction
was associated with elevated risk of SCD and with a consistent
benefit from n−3 PUFA (Macchia et al., 2005). This was the
core hypothesis of the GISSI-HF Trial, a randomized, placebo-
controlled trial investigating the efficacy of n−3 PUFA (850–
882 mg EPA and DHA daily as ethyl ester compared to placebo)
in 6975 patients who had clinical evidence of HF, classified as
NYHA class II–IV, followed for a median of 3.9 years (Tavazzi
et al., 2004, 2008). Statistically significant risk reductions in the
two co-primary endpoints were observed in n−3 PUFA treated
patients: 9% (adjusted HR 0.91; 95% CI: 0.833–0.998; P = 0.041)
and 8% (adjusted HR 0.92; 95% CI: 0.849–0.999; P = 0.009) for
mortality and mortality plus admission to hospital for CV rea-
son, respectively (Table 2). It might be argued that the benefit
showed by n−3 PUFA in HF patients is only marginal, being
modest as the amount of relative risk reduction was modest. Actu-
ally, due to the high mortality and hospitalization rates in HF
patients, the relative risk reduction observed in GISSI-HF can be
translated into an absolute benefit of 18 deaths avoided and 17
prevented CV hospitalizations for every 1000 patients treated for
3.9 years with n−3 PUFA, i.e., a not trivial benefit as compared to
statins and ACE-inhibitors in high-risk populations (Yusuf et al.,
2000; Heart Protection Study Collaborative Group, 2002). The
main study results were consistent with those of the secondary
analyses, which were predefined in the study protocol, for (a) base-
line characteristics, (b) secondary outcomes, and (c) per-protocol
analysis in the 4994 patients who were compliant to experimen-
tal treatments. Worsening of HF and presumed arrhythmic death
accounted for 62% of all deaths and were lower in the n−3 PUFA
as compared to placebo group. Almost half of the absolute reduc-
tion of risk of death due to n−3 PUFA treatment was attributable
to the reduction of ventricular arrhythmias (mortality: 0.9% out
of 1.8%; first CV hospitalization: 1.0% out of 1.7%). Moreover,
the rate of total major ventricular arrhythmias, defined as the
occurrence of arrhythmic death or hospitalization due to ven-
tricular arrhythmias, was significantly reduced early after the start
of treatment in the 3 PUFA group (Marchioli et al., submitted).
These findings support the idea that also in the clinical setting of
HF n−3 PUFA may exert their antiarrhythmic effect. In addition,
the benefit in both co-primary endpoints (mortality and hospi-
talization) suggests that n−3 PUFA might positively affect the
pathophysiologic mechanisms leading to the progression of HF
(Marchioli et al., 2009; Ghio et al., 2010). GISSI-HF Trial had some
weaknesses and limitations. The patients enrolled in the GISSI-
HF trial were already treated with guideline-based therapies for
HF, so the benefit of n−3 PUFA can be considered as additive
to the one determined by recommended treatments. Moreover,
GISSI-HF trial adopted a pragmatic strategy, representing what
happens in real-world settings of clinical practice. This assures the
transferability of the GISSI-HF results to all patients with HF and
suggest to not consider a limitation the apparent high percentages
of patients who were not fully compliant with experimental treat-
ments (by the end of the study 28.7% in the n−3 PUFA group and
29.6% in the placebo group). Although the observed benefit was
lower than expected, it is comparable to the one obtained by the use
of chronic preventive treatments in other clinical settings (Yusuf
et al., 2000; Heart Protection Study Collaborative Group, 2002).
On the other side, the high percentage of fully treated patients may
have left limited room to further improvement. The low number of
patients with preserved left ventricular ejection fraction (<10%)
may be partially considered as a limitation since it precluded to
perform a reliable assessment of the effect of n−3 PUFA in this
subgroup of patients.
PATIENTS WITH IMPLANTABLE CARDIOVERTER
DEFIBRILLATOR
Few studies evaluated the antiarrhythmic effect of n−3 PUFA in
patients with ICD, reporting mixed results. Two hundred patients
with a recent episode of sustained ventricular tachycardia (VT) or
ventricular fibrillation (VF) and implanted ICD were randomly
assigned to receiven−3 PUFA, 1.8 g/day, or placebo in trial by Raitt
et al. (2005) At a median follow-up of 718 days,n−3 PUFA did not
prevent episodes of VT or VF. Overall, n−3 PUFA treatment was
associated with a trend toward a higher incidence of the primary
endpoint (time to ICD therapy for VT/VF; P = 0.19), a significant
increased rate of recurrent episodes of VT/VF (P < 0.001) and,
in patients with VT as the qualifying entry rhythm, a significant
increase in the primary endpoint (P= 0.007).
One year after this first trial, the results of The Study on Omega-
3 Fatty acids and ventricular Arrhythmia (SOFA) have been pub-
lished (Brouwer et al., 2006). The SOFA trial was a randomized,
parallel, placebo-controlled, double-blind study evaluating the
effect of n−3 PUFA 2 g/day for a median period of 356 days, on
appropriate ICD intervention for VT or VF, or all-cause death
in 546 patients with ICD and prior documented malignant VT
or VF. No statistically significant protective effect in n−3 PUFA
group was shown (HR 0.86; 95% CI: 0.64–1.16; P= 0.33).
As to the results of these two trials, some aspects of study design
have to be considered. The first point is the type of population
enrolled in these studies. Approximately 23% of patients in the
trial of Raitt et al. (2005), and the 30% in SOFA had no history
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of CHD. The best evidence for the antiarrhythmic action of n−3
PUFA has been produced by experimental work performed in
ischemia-mediated animal models and in clinical trials carried
out in post-MI patients, in which ischemia-triggered arrhythmias
may be predominant. Consequently, it has been hypothesize that
n–3 PUFA may have a more favorable effect in patients in whom
the specific clinical setting and underlying arrhythmogenic mech-
anisms of initiation and propagation may be more susceptible to
the antiarrhythmic effects of n–3 PUFA (Leaf et al., 2003). The
second aspect is the primary endpoint used in ICD trials, i.e.,
VT or VF. It certainly may address the influence of n–3 PUFA
on the risk of ventricular arrhythmias, however it might not be
the ideal surrogate for the risk of sudden death. Although VT
may frequently degenerate in VF and consequently in a sudden
death, the spontaneous resolution of this ventricular arrhythmia
is not uncommon. We cannot exclude that the treatment with
n–3 PUFA might increase this favorable event, impossible to be
showed in patients with ICD because of the device intervention.
Moreover caring physicians were allowed to program ICD as more
appropriate for their patients, so it has to be taken into consider-
ation that this may represent a possible bias. Another aspect to be
considered is the statistical power of the two studies. The power
of trial by Raitt was significantly weakened by the low event rate
observed in the placebo group as compared with the expected
one. In addition, the observed reduction of events was lower than
expected (Table 3). The total event rate of the primary endpoint
observed in SOFA (33%) was close to the expected one (35%), but
the observed efficacy of n–3 PUFA was lower than the expected
one that was used for sample size calculation. Accordingly, SOFA
had a 69% power to detect a 30% event reduction, so it is not
surprising that this study did not detect a significant reduction in
the primary endpoint (Table 3).
At variance with these two studies, in the FAAT study (Leaf et al.,
2005) the administration of 2.6 g/day of n–3 PUFA vs. placebo in
402 patients at high-risk for fatal ventricular arrhythmias showed
a trend toward a reduction of the primary endpoint (risk reduc-
tion of −28% of the time to the first ICD event for VT or VF, or
death from any cause; P = 0.057). Although the choice to include
all-cause death in the primary endpoint might be criticized, when
probable and definite episodes of VT or VF were used as outcome
measure, a statically significant relative risk reduction of 31% was
obtained (P = 0.033; Leaf et al., 2005).
Two meta-analyses of data collected in these three trials did
not support a protective effect of n−3 PUFA on cardiac arrhyth-
mias. The first meta-analysis showed a significant heterogeneity
between trials, and no effect of n−3 PUFA on the relative risk of
ICD discharge (RR 0.93; 95% CI: 0.70–1.24; Jenkins et al., 2008).
The second meta-analysis, confirmed the existence of a consider-
able heterogeneity between the trials, and showed no convincing
protective effect of n−3 PUFA on time to first confirmed VF or
VT combined with death (RR 0.90; 95% CI: 0.67–1.22), although
the HR for the subgroup of patients with coronary artery disease
at baseline tended toward a protective effect (RR 0.79; 95% CI:
0.60–1.06; Brouwer et al., 2009).
The results of a GISSI-HF sub-study assessing the antiarrhyth-
mic effect of n−3 PUFA in 566 patients with HF enrolled who
had received an ICD for secondary or primary prevention of VF
or VT have been recently published (Finzi et al., 2011). The pri-
mary endpoint (defined as time to first appropriate ICD discharge
for VT/VF; adjusted HR= 0.80, 95% CI: 0.59–1.09, P = 0.152),
and the number of ICD discharges were not significantly altered
(P = 0.30) by n−3 PUFA treatment.
The meta-analysis of these four trials on n−3 PUFA in patients
with implanted ICD did not demonstrate a significant antiarrhyth-
mic effect of n−3 PUFA (OR 0.82; 95% CI: 0.67–1.01; P = 0.06;
Figure 1).
PATIENTS AT RISK OF SUPRAVENTRICULAR
TACHYARRHYTHMIAS
Although results of observational studies suggested positive effects
of n−3 PUFA in reducing the number of episodes as well as
the burden of atrial tachyarrhythmia (Biscione et al., 2005), ran-
domized control studies showed discrepant results (Table 4). An
open-label, prospective, randomized, controlled trial with par-
allel groups, tested the effect of 2 g/day of n−3 PUFA on the
development of AF in the postoperative period in 160 patients
undergoing coronary artery by-pass grafting (CABG; Calo et al.,
2005). Its results showed that n−3 PUFA administration before
and during hospitalization substantially reduced the incidence of
postoperative AF by 54.4% and was associated with a shorter hos-
pital stay as compared the control group. In 199 patients with
persistent AF treated with amiodarone and a renin-angiotensin-
aldosterone system inhibitor, the addition of n−3 PUFAs 2 g/day
improved the probability of the maintenance of sinus rhythm
at 1 year after direct current cardioversion (Nodari et al., 2011).
At variance with the previous study, a prospective, randomized,
double-blind, placebo-controlled, parallel-group multicenter trial
involving 663 outpatient participants with previous confirmed
symptomatic paroxysmal (n= 542) or persistent (n= 121) AF
reported no difference between treatment groups (n−3 PUFA
8 g/day or placebo for the first 7 days; n−3 PUFA 4 g/day or
placebo thereafter through week 24) for recurrence of symp-
tomatic AF in the paroxystic AF stratum (HR, 1.15; 95% CI:
0.90–1.46; P = 0.26), in the persistent AF stratum (HR, 1.64;95%
CI: 0.92–2.92; P = 0.09), and in both strata combined (HR, 1.22;
95% CI: 0.98–1.52; P = 0.08; Kowey et al., 2010).
A recent systematic review and meta-analysis of published
randomized trial regarding n−3 PUFA supplementation for AF
prevention on 1955 patients showed a significant heterogeneity
among the studies [P = 0.002, I (2)= 65.0%] and did not find
a significant reduction in the risk for AF (OR 0.81, 95% CI:
0.57–1.15; P = 0.24; Liu et al., 2011).
The discrepant results on the benefit of n−3 PUFA in pre-
venting supraventricular tachyarrhythmia in the above discussed
trials may be due to several reasons. The role of several patient
characteristics were probably underestimated.
Left atrial dimension, AF duration, recurrent episodes of AF,
which reduced the possibilities of restore or maintain a stable sinus
rhythm (Suzuki et al., 2011; Pisters et al., 2012), were nor included
among inclusion criteria neither in subgroup analysis in all but
one of the studies. Nodari et al. (2011) showed that the main cor-
relates of AF recurrence were, other than n−3 PUFA, the duration
of AF before randomization, left atrial dimension, and left ventric-
ular ejection fraction, suggesting that atrial remodeling may play
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a role in this clinical setting. Similarly to the case of drugs inhibit-
ing renin-angiotensin system, clinical success in restoring sinus
rhythm is likely to be achievable only before the underlying atrial
remodeling may have gone too far to be reversed (Savelieva et al.,
2011). Baseline plasma levels of n−3 PUFA may have influenced
the antiarrhythmic effect of oral supplementation (Skuladottir
et al., 2011), and the use of new-onset, postoperative AF may not be
the ideal model to assess the effect of n−3 PUFA on new-onset AF.
To date, as Camm and Savelieva (2011) affirmed in their edi-
torial comment to the Nodari’s article, the antiarrhythmic effect
of n−3 PUFA in AF has not been demonstrated in randomized
clinical trial. A large scale randomized controlled trial testing the
effect of n−3 PUFA on supraventricular arrhythmias in patients
undergoing to cardiac surgery is currently ongoing (Mozaffarian
et al., 2011). Its results will increase our knowledge on the antiar-
rhythmic effects as well as on tolerability of n−3 PUFA in this
clinical setting.
REVIEWS AND META-ANALYSES
The effect of n−3 PUFA on cardiovascular events and SCD has
been analyzed in some reviews and meta-analyses.
A Cochrane review (Hooper et al., 2004) and a meta-analysis
(Hooper et al., 2006) did not find a benefit of n−3 PUFA admin-
istration. The Cochrane review (Hooper et al., 2004), which
included 89 studies (48 randomized controlled studies and 41
cohort studies), found that n−3 PUFA did not cause a signifi-
cant reduction in the risk of total mortality (RR 0.87; 95% CI:
0.73–1.03) or combined CV events (RR 0.95; 95% CI: 0.82–1.12).
Considerable debate was generated by the choice of inclusion
of the DART II (Burr et al., 2003) in the analysis, because of
various limitations of the study and the difficulties occurring dur-
ing its conduct (von Schacky et al., 2006; Graham et al., 2007;
von Schacky and Harris, 2007). After excluding DART II from
the Cochrane analysis, the reduction of total death became sta-
tistically significant (RR 0.83; 95% CI: 0.75–0.91), although the
risk of CV events did not change (Hooper et al., 2004). More
recently a review, at variance with the previous ones, pooled the
effect on SCD of eight trials, comprising 20,997 patients, and
showed that the treatment with n−3 PUFA was able to signifi-
cantly reduce the incidence of SCD (RR 0.43; 95% CI: 0.20–0.91)
in post-MI patients. In patients with angina the risk of SCD
was increased (RR 1.39; 95% CI: 1.01–1.92) and overall, n−3
PUFA had no effect on cardiac death and all-cause mortality (RR
0.71 and 0.77; 95% CI: 0.50–1.00 and 0.58–1.01, respectively;
Zhao et al., 2009). In 2010 a meta-analysis of 29 randomized
controlled trials, comprising 35.144 patients, showed that n−3
PUFA treatment was not associated with a statistically signifi-
cant decreased mortality (RR 0.88; 95% CI: 0.64–1.03) although
the probability of some benefits was high (0.93; Filion et al.,
2010). A recent meta-analysis, including 20.485 patients with a
history of CVD, showed that n−3 PUFA supplementation did
not reduce the risk of overall CV events (RR 0.99; 95% CI: 0.89–
1.09), all-cause mortality, SCD, MI, HF, or transient ischemic
attack and stroke (Kwak et al., 2012). About the results of this last
meta-analysis several aspects deserve to be considered, e.g., most
studies were very small, not designed to evaluate CV endpoints
and with a short follow-up, the methodological choice of using
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FIGURE 1 | Pooled analysis of the effect of n-3 PUFA on appropriate ICD intervention.
random-effects models in the primary analysis, and the exclu-
sion of two large open-label trials (Gruppo Italiano per lo Studio
della Sopravvivenza nell’Infarto miocardico, 1999;Yokoyama et al.,
2007).
CONCLUSION
The evidence available to date seem to suggest n−3 PUFA having
an antiarrhythmic effects, but no firm conclusion can be drawn.
The stronger evidence on positive effects of n−3 PUFA in reduc-
ing SCD came from studies including patients with CHD. In
patients with symptomatic HF, n−3 PUFA seem to reduce signifi-
cantly ventricular arrhythmias and SCD. Such effect on ventricular
arrhythmia has not been convincingly confirmed so far by the
results of trials in carriers of an ICD, though the meta-analysis of
the studies in ICD patients is very suggestive. On the other side, the
effect on recurrent/new-onset AF is still controversial. Many of the
clinical trials conducted so had not significant results. The main
cause of this “failure” is the inadequate power of the studies due to
either low rate of events or the overoptimistic expectations of the
benefit of n−3 PUFA used for sample size calculation. Serum base-
line levels of n−3 PUFA and different doses may have contributed
to such results.
In conclusion, the still debated antiarrhythmic effect of n−3
PUFA needs to be investigated in larger and/or more efficient
trials than those conducted so far. On this regard it is possible
that a more accurate selection of patients, e.g., evaluating relevant
biological parameters and markers (type and length of AF, left
atrial dimensions, plasma and cellular n−3 PUFA levels, systemic
inflammatory status, or oxidative stress), a standardization in the
device programming in ICD patient populations, and a “realis-
tic” sample size calculation might answer some of the still open
question on the antiarrhythmic effect of n−3 PUFA.
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